Market Opportunity with Epi One
We believe Epi One is at the vanguard of the rapidly evolving cancer diagnostics sector, presenting a unique investment prospect.
Why Consider Investing in Epi One?
Market Growth:
The U.S. Cancer Diagnostics Market is on course to reach $70 billion by 2032, propelled by a projected annual growth rate of 8.4% starting from 2023.
Global Market Expansion:
Looking globally, the world cancer diagnostics market is anticipated to achieve $258 billion by 2030. Epi One aims to tap into this expansive market with our innovative diagnostic solutions, broadening our impact and potential.
Technological Inflection Point:
At the core of our strategy, Epi One leverages advanced DNA-based biomarker identification methods. We believe these techniques can be faster and more accurate than traditional diagnostics, positioning us at a pivotal moment within the industry.
Investing in Epi One is a commitment to advancing a future where cancer can be detected early enough to be treated effectively, potentially saving millions of lives worldwide.
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
